These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27526980)

  • 1. Response to pemetrexed rechallenge after acquired resistance of ALK inhibitors.
    Miyazaki K; Satoh H; Tamura T
    Lung Cancer; 2016 Dec; 102():135. PubMed ID: 27526980
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
    Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
    Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
    Zhao N; Zheng SY; Yang JJ; Zhang XC; Xie Z; Xie B; Su J; Chen ZH; Chen SL; Zhang N; Lou NN; Dong S; Wu YL
    Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
    [No Abstract]   [Full Text] [Related]  

  • 5. [Association between the ALK Gene Status and the Efficacy of First-line 
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
    Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response to crizotinib retreatment after acquisition of drug resistance.
    Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
    J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
    [No Abstract]   [Full Text] [Related]  

  • 7. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
    Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.
    Takegawa N; Hayashi H; Iizuka N; Takahama T; Ueda H; Tanaka K; Takeda M; Nakagawa K
    Ann Oncol; 2016 May; 27(5):953-5. PubMed ID: 26811347
    [No Abstract]   [Full Text] [Related]  

  • 9. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
    Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
    Ou W; Li N; Wang SY; Li J; Liu QW; Huang QA; Wang BX
    Cancer; 2016 Mar; 122(5):740-7. PubMed ID: 26700505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
    Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS signaling in ALK fusion lung cancer.
    Hrustanovic G; Bivona TG
    Small GTPases; 2016; 7(1):32-3. PubMed ID: 26901483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin 
in Patients with IIIa Lung Adenocarcinoma].
    Zhang S; Xu P; Yuan C; Ou W
    Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):365-8. PubMed ID: 26104893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
    Shi SB; Wang M; Tian J; Li R; Chang CX; Qi JL
    Transl Res; 2016 Apr; 170():1-7. PubMed ID: 26687391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
    Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
    Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies.
    Kobayashi Y; Sakao Y; Ito S; Park J; Kuroda H; Sakakura N; Usami N; Mitsudomi T; Yatabe Y
    J Thorac Oncol; 2013 Aug; 8(8):e75-8. PubMed ID: 23857406
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
    Li S; Zhou F; Ren S; Zhou C
    Lung Cancer; 2014 May; 84(2):203-5. PubMed ID: 24636847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.